BresaGen in cell delivery deal with Stanford
This article was originally published in Clinica
Executive Summary
Australian biotechnology company BresaGen is to sponsor a research programme at Stanford University in the US that aims to develop an image-guided cell delivery device with the capacity to monitor cell metabolism following transplant of cells into the brains of patients with Parkinson's disease. BresaGen's chief scientific officer, Allan Robins, said that by monitoring cell metabolism, the therapeutic efficacy of cell therapy for Parkinson's disease might be significantly enhanced.